
|Articles|January 1, 2003
Systemic retinoid chemoprophylaxis causes frequent adverse events for immunosuppressed transplant patients with advanced SCC
Chicago -- Although published clinical trial results suggest systemic retinoid therapy administered for skin cancer chemoprevention in immunosuppressed organ transplant recipients is well tolerated despite causing frequent adverse events,
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















